Company intelligence / Profile preview

Perfuze

Galway City, County Galway, Irelandperfuze.com ↗

Ownership: Private
Employees: ~38
Development stage: Commercial

Overview

Perfuze has developed and commercialized the Millipede 088 device for mechanical thrombectomy in acute ischemic stroke. The product has received CE Mark approval and has been used to successfully treat its first cohort of patients. The company claims its superbore aspiration technology enables rapid and complete clot removal with improved clinical outcomes and shorter procedure times.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically, catheter-based aspiration technology)
Industry: Surgical Medical Devices

Drug pipeline

2 assets

Zipline

Commercial

Indications: Acute ischemic stroke

1 more asset in the full pipeline.

Request access →

Partnerships

Not specifically disclosed; investors include major life sciences VCs such as Seroba Life Sciences, LSP, SV Health Investors.

Beyond the preview

Go deeper on Perfuze.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perfuze.

Explore the full profile